ABCL Q3 2025 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+37.6% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$76M-851.8% margin

Net Income

-$57M-637.8% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-47.6%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$62M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$392M

Stockholders' Equity

$964M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$7M	+37.6%
Gross Profit	$9M	$7M	+37.6%
Operating Income	-$76M	-$94M	+18.6%
Net Income	-$57M	-$51M	-11.8%

Revenue Segments

Research Fees

$9M98%

License

$138,0002%